(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are MAJOREL GROUP LUX, TECHSTEP, and ADC SIIC.

The three biggest losers today are BERGENBIO, NANOBIOTIX, and TELEPERFORMANCE.

Winners today

1. MAJOREL GROUP LUX (MAJ.AS)

38.19% Price Change

Majorel Group Luxembourg S.A. engages in the designing, building, and delivering end-to-end customer experience (CX) solutions for digital-native and vertical leading brands worldwide. It offers customer interaction services, such as solutions for customer services, sales and marketing, loyalty and retention, and tech support; business process services, including content services, trust and safety, and vertical business process outsourcing services; and tech and expert services comprising digital consumer engagement, CX consulting, start-ups, and vertical digital solutions. The company serves Internet, banking and financial services, insurance, automotive, consumer products and retail, travel and hospitality, utilities and energy, and telecoms and media industries. Majorel Group Luxembourg S.A. was incorporated in 2018 and is headquartered in Luxembourg City, Luxembourg.

AEX-Index ended the session with MAJOREL GROUP LUX rising 38.19% to €28.95 on Wednesday, after three sequential sessions in a row of gains. AEX-Index slid 0.77% to €749.60, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, MAJOREL GROUP LUX has a trailing twelve months EPS of €1.78.

PE Ratio

MAJOREL GROUP LUX has a trailing twelve months price to earnings ratio of 16.26. Meaning, the purchaser of the share is investing €16.26 for every euro of annual earnings.

Volume

Today’s last reported volume for MAJOREL GROUP LUX is 1419800 which is 7904.71% above its average volume of 17737.

More news about MAJOREL GROUP LUX.

2. TECHSTEP (TECH.OL)

20% Price Change

Techstep ASA operates as a mobile technology enabler in Norway, Sweden, Denmark, and Poland. It offers mobile hardware, service, support, and mobility consultancy services; software as a service, as well as mobile expense management modules; and financing and remarketing services. The company also provides industry-leading cloud-based PBX solutions and enterprise mobility management services, including mobile security, system design, implementation, and mobile device management. In addition, it develops and provides enterprise mobility software and solutions for the customers in the transportation, logistics, and public safety sectors, as well as offers mobile device lifecycle management solutions. The company was founded in 2016 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with TECHSTEP jumping 20% to €1.50 on Wednesday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, TECHSTEP has a trailing twelve months EPS of kr-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.18%.

More news about TECHSTEP.

3. ADC SIIC (ALDV.PA)

15.38% Price Change

Alliance Developpement Capital SIIC (ADC SIIC) is a publicly owned real estate investment firm. The firm specializes in owning and managing residential real estate properties. It primarily invests in properties in Paris and its suburbs. The firm was formerly known as AD Capital SA. Alliance Developpement Capital is based in Saint-Josse-Ten-Noode, Belgium.

CAC 40 ended the session with ADC SIIC jumping 15.38% to €0.08 on Wednesday, after five sequential sessions in a row of losses. CAC 40 slid 0.86% to €7,466.66, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, ADC SIIC has a trailing twelve months EPS of €-0.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.85%.

Yearly Top and Bottom Value

ADC SIIC’s stock is valued at €0.08 at 22:40 EST, way under its 52-week high of €0.09 and way above its 52-week low of €0.06.

More news about ADC SIIC.

4. GENSIGHT BIOLOGICS (SIGHT.PA)

15.11% Price Change

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

CAC 40 ended the session with GENSIGHT BIOLOGICS jumping 15.11% to €0.64 on Wednesday while CAC 40 fell 0.86% to €7,466.66.

Earnings Per Share

As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.17.

More news about GENSIGHT BIOLOGICS.

5. ORPEA (ORP.PA)

12.64% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA rising 12.64% to €2.71 on Wednesday while CAC 40 fell 0.86% to €7,466.66.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-5.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.36%.

Yearly Top and Bottom Value

ORPEA’s stock is valued at €2.71 at 22:40 EST, way under its 52-week high of €35.16 and way above its 52-week low of €1.74.

Volume

Today’s last reported volume for ORPEA is 1998680 which is 30.39% below its average volume of 2871400.

More news about ORPEA.

6. SATS (SATS.OL)

11.46% Price Change

Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. The company offers sportswear, fitness gear, bars, and energy drinks. It operates 262 fitness clubs under the SATS, ELIXIA, Fresh Fitness, HiYoga, and Mentra brands. The company was founded in 1995 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with SATS jumping 11.46% to €10.02 on Wednesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI rose 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, SATS has a trailing twelve months EPS of kr-0.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.63%.

Volatility

SATS’s last week, last month’s, and last quarter’s current intraday variation average was 0.98%, 1.28%, and 2.28%.

SATS’s highest amplitude of average volatility was 1.78% (last week), 2.14% (last month), and 2.28% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 3.2% and a drop 266.7% for the next.

More news about SATS.

7. KORIAN (KORI.PA)

8.73% Price Change

Korian provides a range of medical and non-medical care and support services for the elderly and people with short or longer-term health issues. The company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers home care, support, and hospitalization services. As of December 31, 2021, it operated with 91,808 beds. The company operates approximately 850 care facilities and networks in France, Germany, Italy, Spain, the Netherlands, and Belgium. The company was formerly known as Korian-Medica S.A. and changed its name to Korian in July 2015. Korian was founded in 2001 and is based in Paris, France.

CAC 40 ended the session with KORIAN rising 8.73% to €7.60 on Wednesday while CAC 40 dropped 0.86% to €7,466.66.

Earnings Per Share

As for profitability, KORIAN has a trailing twelve months EPS of €0.3.

PE Ratio

KORIAN has a trailing twelve months price to earnings ratio of 25.33. Meaning, the purchaser of the share is investing €25.33 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, KORIAN’s stock is considered to be overbought (>=80).

More news about KORIAN.

8. KAHOOT! (KAHOT.OL)

7.59% Price Change

Kahoot! ASA operates a learning and engagement platform in the United States, Canada, Europe, the Asia Pacific, the Latin America and the Caribbean, Africa, the Middle East, and India. The company's platforms help to create, share, and host learning sessions. It offers Kahoot! Learning platform for learning and engagement services; employee engagement and learning platforms, such as Actimo and Motimate; Drops, a language learning app for visuals and play; Kahoot! DragonBox app for math learning; and Kahoot! Poio Read app, which empowers children to learn to read through play. The company also provides Kahoot! Academy, a global community and knowledge platform for all creators, learners and learning providers; Kahoot! 360 Spirit; Kahoot! Marketplace, an emerging global digital marketplace for learning resources on Kahoot; Kahoot! EDU support program, a site license for schools and districts; and Whiteboard.fi, an online whiteboard that provides learning tools for educators, teachers, and classrooms. In addition, it offers Kahoot! Zoom App platform for engagement and learning to virtual meetings and events; and Clever, a single sign-on digital learning platform for teachers and students. Kahoot! ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with KAHOOT! jumping 7.59% to €26.21 on Wednesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI jumped 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, KAHOOT! has a trailing twelve months EPS of kr0.05.

PE Ratio

KAHOOT! has a trailing twelve months price to earnings ratio of 524.2. Meaning, the purchaser of the share is investing kr524.2 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.38%.

Sales Growth

KAHOOT!’s sales growth for the next quarter is 17.2%.

Yearly Top and Bottom Value

KAHOOT!’s stock is valued at kr26.21 at 22:40 EST, way under its 52-week high of kr29.38 and way higher than its 52-week low of kr15.05.

More news about KAHOOT!.

9. NICOX (COX.PA)

7.41% Price Change

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

CAC 40 ended the session with NICOX rising 7.41% to €0.59 on Wednesday, after five consecutive sessions in a row of losses. CAC 40 fell 0.86% to €7,466.66, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, NICOX has a trailing twelve months EPS of €-1.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.38%.

Moving Average

NICOX’s worth is way below its 50-day moving average of €0.73 and way under its 200-day moving average of €1.37.

Yearly Top and Bottom Value

NICOX’s stock is valued at €0.59 at 22:40 EST, way under its 52-week high of €2.09 and higher than its 52-week low of €0.57.

More news about NICOX.

10. SMARTCRAFT (SMCRT.OL)

6.97% Price Change

SmartCraft ASA provides software solutions to the construction industry in Norway, Sweden, and Finland. The company offers Cordel; Bygglet, a SaaS born in the cloud solution; EL-VIS, a solution for electricians; and Congrid, a cloud-based tool for project management in construction companies. It also provides HomeRun, a digital tool for construction, project communication, document, and procurement management; Kvalitetskontroll, a cloud-based project management solution and quality assurance platform for construction companies; El-verdi, a digital sales tool for electricians; and ELinn, a cloud based solution for electricians to handle project management services. The company was founded in 1987 and is headquartered in Hønefoss, Norway.

Oslo Børs Benchmark Index_GI ended the session with SMARTCRAFT rising 6.97% to €19.95 on Wednesday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, SMARTCRAFT has a trailing twelve months EPS of kr0.38.

PE Ratio

SMARTCRAFT has a trailing twelve months price to earnings ratio of 52.5. Meaning, the purchaser of the share is investing kr52.5 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.

More news about SMARTCRAFT.

Losers Today

1. BERGENBIO (BGBIO.OL)

-53.55% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase II clinical development that focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and COVID-1. The company is also developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase Ib clinical trial. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO falling 53.55% to €2.10 on Wednesday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-3.31.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO’s stock is considered to be overbought (>=80).

More news about BERGENBIO.

2. NANOBIOTIX (NANO.PA)

-15.03% Price Change

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

CAC 40 ended the session with NANOBIOTIX falling 15.03% to €2.04 on Wednesday while CAC 40 fell 0.86% to €7,466.66.

Earnings Per Share

As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -198.69%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.8%, now sitting on 2.66M for the twelve trailing months.

Moving Average

NANOBIOTIX’s value is way below its 50-day moving average of €3.37 and way under its 200-day moving average of €3.70.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NANOBIOTIX’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for NANOBIOTIX is 383350 which is 588.72% above its average volume of 55661.

More news about NANOBIOTIX.

3. TELEPERFORMANCE (TEP.PA)

-13.7% Price Change

Teleperformance SE, together with its subsidiaries, engages in the provision of outsourced customer and citizen experience management, and related services in France and internationally. The company operates in two segments, Core Services and Digital Integrated Business Services, and Specialized Services. The Core Services and Digital Integrated Business Services segment offers customer and citizen care; customer relationship operations; technical support; and technical assistance and customer acquisition services, as well as back-office solutions and integrated services, including social media content moderation services and data labeling for automation solutions; and knowledge services in the field of analytics solutions, automated systems, and artificial intelligence. The company also manages business processes, as well as provides digital platform, consulting, and data analysis services; and business process outsourcing services for government agencies. The Specialized Services segment provides on-line interpretation, visa application management, health management services, and accounts receivable credit management services. It also offers digital recruitment process outsourcing; consumer health management business services and related digital solutions integration; translation and interpreting services; and business process outsourcing services for government agencies in the United States. The company serves automotive, energy and utilities, insurance, public sector, technology, travel and hospitality, and banking and financial services, as well as healthcare, media, retail and e-commerce, crypto, cargo, telecom, and video games industries. Teleperformance SE was incorporated in 1989 and is headquartered in Paris, France.

CAC 40 ended the session with TELEPERFORMANCE falling 13.7% to €175.80 on Wednesday, following the last session’s downward trend. CAC 40 fell 0.86% to €7,466.66, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, TELEPERFORMANCE has a trailing twelve months EPS of €10.8.

PE Ratio

TELEPERFORMANCE has a trailing twelve months price to earnings ratio of 16.28. Meaning, the purchaser of the share is investing €16.28 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.89%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 8.15B for the twelve trailing months.

Sales Growth

TELEPERFORMANCE’s sales growth for the current quarter is 7.8%.

More news about TELEPERFORMANCE.

4. INVENTIVA (IVA.PA)

-12.59% Price Change

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

CAC 40 ended the session with INVENTIVA falling 12.59% to €1.91 on Wednesday, following the last session’s downward trend. CAC 40 slid 0.86% to €7,466.66, after two successive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, INVENTIVA has a trailing twelve months EPS of €-1.3.

More news about INVENTIVA.

5. SEQUANA MEDICAL (SEQUA.BR)

-11.59% Price Change

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL dropping 11.59% to €3.05 on Wednesday while BEL 20 dropped 0.79% to €3,795.60.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.29.

Volume

Today’s last reported volume for SEQUANA MEDICAL is 119984 which is 965.95% above its average volume of 11256.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 923k for the twelve trailing months.

Moving Average

SEQUANA MEDICAL’s value is way below its 50-day moving average of €5.31 and way below its 200-day moving average of €5.90.

More news about SEQUANA MEDICAL.

6. NYXOAH (NYXH.BR)

-10.8% Price Change

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with NYXOAH dropping 10.8% to €7.10 on Wednesday while BEL 20 dropped 0.79% to €3,795.60.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.22%.

More news about NYXOAH.

7. ASETEK (ASTK.OL)

-10.63% Price Change

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Oslo Børs Benchmark Index_GI ended the session with ASETEK dropping 10.63% to €3.70 on Wednesday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.02% to €1,204.81, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.98.

Volatility

ASETEK’s last week, last month’s, and last quarter’s current intraday variation average was a negative 15.91%, a positive 2.65%, and a positive 8.64%.

ASETEK’s highest amplitude of average volatility was 21.69% (last week), 17.80% (last month), and 8.64% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ASETEK’s stock is considered to be overbought (>=80).

More news about ASETEK.

8. ASM INTERNATIONAL (ASM.AS)

-10.05% Price Change

ASM International NV, together with its subsidiaries, engages in the research, development, manufacture, marketing, and servicing of equipment and materials used to produce semiconductor devices in the United States, Europe, and Asia. Its products include wafer processing deposition systems for single-wafer atomic layer deposition, plasma enhanced chemical vapor deposition, epitaxy, silicon carbide, vertical furnace systems, and low pressure chemical vapor deposition and diffusion products, as well as provides spare parts and support services. The company also manufactures and sells equipment, which is used in wafer processing, encompassing the fabrication steps in which silicon wafers are layered with semiconductor devices. It offers its products to semiconductor manufacturers. The company was formerly known as Advanced Semiconductor Materials International NV. ASM International NV was incorporated in 1968 and is headquartered in Almere, the Netherlands.

AEX-Index ended the session with ASM INTERNATIONAL sliding 10.05% to €310.05 on Wednesday, following the last session’s downward trend. AEX-Index fell 0.77% to €749.60, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, ASM INTERNATIONAL has a trailing twelve months EPS of €7.9.

PE Ratio

ASM INTERNATIONAL has a trailing twelve months price to earnings ratio of 39.25. Meaning, the purchaser of the share is investing €39.25 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.59%.

More news about ASM INTERNATIONAL.

9. NAPATECH (NAPA.OL)

-9.43% Price Change

Napatech A/S offers reconfigurable computing solutions for the networking and cybersecurity applications worldwide. The company provides Link Capture Software that enables packet capture with nanosecond timestamping and replay with precise inter-frame gap control; Link Inline Software, which offers a processing architecture that offloads and accelerates flow aware application data planes; Link Virtualization Software that offloads and accelerates the Open vSwitch data plane to enhance CPU efficiency and network performance; and Link Programmable, which enables end users and OEMs to deploy FPGA computation solutions. It also offers solutions for telecom operators, cloud and data center service providers, and infrastructure and defense, as well as financial services, cyber security, network management, and virtualization. The company was incorporated in 2003 and is headquartered in Copenhagen, Denmark.

Oslo Børs Benchmark Index_GI ended the session with NAPATECH falling 9.43% to €9.60 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.02% to €1,204.81.

Earnings Per Share

As for profitability, NAPATECH has a trailing twelve months EPS of kr-0.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.53%.

Sales Growth

NAPATECH’s sales growth for the current quarter is negative 35.7%.

More news about NAPATECH.

10. AKER CARBON CAPTUR (ACC.OL)

-9.41% Price Change

Aker Carbon Capture ASA provides products, technology, and solutions within the field of carbon capture technologies, utilization, and storage in Norway and internationally. The company's carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. It offers carbon capture plants under the Just Catch and Big Catch brands. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Carbon Capture ASA is a subsidiary of Aker Horizons Holding AS.

Oslo Børs Benchmark Index_GI ended the session with AKER CARBON CAPTUR falling 9.41% to €10.20 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.02% to €1,204.81.

Earnings Per Share

As for profitability, AKER CARBON CAPTUR has a trailing twelve months EPS of kr-0.32.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER CARBON CAPTUR’s stock is considered to be overbought (>=80).

Volatility

AKER CARBON CAPTUR’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.36%, a negative 1.09%, and a positive 3.24%.

AKER CARBON CAPTUR’s highest amplitude of average volatility was 2.36% (last week), 3.11% (last month), and 3.24% (last quarter).

More news about AKER CARBON CAPTUR.

Stay up to date with our winners and losers daily report